euglycemic dka glp 1 GLP-1 receptor agonists causing ketoacidosis in patients without diabetes: a brief review GLP-1 Drugs and Type 1

Thanacoody H, Nijhout H, Reed M, Thomas C

Epub 2018 Jan 31

Mayer, C

These initiatives demonstrate a willingness to confront the rise of diabetes with strategies based on health promotion, disease detection, and management of the multiple conditions and complications associated with the disease

many subjects with T2D saw improvements in their blood sugar regulation, too

Market Size & Forecast Global Market Value (2025): USD 65.85 Billion Expected Market Value (2033): USD 236.82 Billion Forecast CAGR (20262033): 17.35% Leading Region in 2025: North America Fastest Growing Region: Asia-Pacific Key Market Trends & Insights North America dominated the Glucagon-Like Peptide 1 (GLP-1) Agonists Market with the largest revenue share of 41.38% in 2025, supported by the high prevalence of type 2 diabetes and obesity, strong adoption of innovative GLP-1 therapies, favorable reimbursement frameworks, and the presence of major pharmaceutical manufacturers